NEPA as antiemetic prophylaxis after failure of 5HT 3 -RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience

Abstract

Introduction

Chemotherapy-induced nausea and vomiting (CINV) may affect adherence to planned chemotherapy treatments and compromise patients’ quality of life during the therapy. NEPA is an oral fixed combination of netupitant, a highly-selective NK₁-RA and palonosetron, a 5HT₃-RA, approved for the prevention of acute and delayed CINV. The aim of this study was to evaluate the efficacy and safety of NEPA with dexamethasone for CINV prophylaxis in the challenging setting of carboplatin and gemcitabine combination chemotherapy, after failure of prophylaxis with 5HT3 receptor antagonist.

Methods

Eligible patients were undergoing carboplatin and gemcitabine combination chemotherapy for metastatic non-small cell lung cancer (NSCLC), ovarian cancer or urothelial cancer and experienced nausea and/or vomiting after the first cycle of chemotherapy, despite an antiemetic prophylaxis with a 5HT₃-RA and dexamethasone. Primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) obtained with NEPA, during the overall phase (0–120 h), after the start of chemotherapy.

Results

During the first cycle of chemotherapy, 15 out of 30 (50%) patients did not properly control CINV with a 5HT₃-RA plus dexamethasone used as primary antiemetic prophylaxis and then were switched to NEPA from the subsequent cycle. During NEPA administration, 13 out of 15 patients (86.7%) achieved an overall CR (no emesis, no rescue medication). Antiemetic treatment with NEPA was very well tolerated with only two patients (13.3%) that experienced a grade 1 TEAE.

Conclusions

Our experience showed that NEPA has proven to be very effective and well tolerated in the prophylaxis of CINV induced by carboplatin-based chemotherapy.

Keywords

Chemotherapy-induced nausea and vomiting netupitant palonosetron ondansetron dexamethasone carboplatin gemcitabine NSCLC ovarian cancer urothelial cancer

Get full access to this article

View all access options for this article.

References

Hesketh

PJ.

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.

Support Care Cancer 1994; 2: 286–292..

de Boer-Dennert

de Wit

Schmitz

, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997; 76: 1055–1061.

Passik

Kirsh

Rosenfeld

, et al. The changeable nature of patients’ fears regarding chemotherapy: implications for palliative care. J Pain Symptom Manage 2001; 21: 113–120.

Hesketh

PJ.

Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting.

Nat Clin Pract Oncol 2005; 2: 196–201.

Zatloukal

Petruzelka

Gemcitabine/carboplatin in advanced non-small cell lung cancer. Lung Cancer 2002; 38: S33–S36

Sufliarsky

Chovanec

Svetlovska

, et al. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer. Neoplasma 2009; 56: 291–297.

Dogliotti

Cartenì

Siena

, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007; 52: 134–141.

Hesketh

Kris

Basch

, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35: 3240–3261.

Roila

Molassiotis

Herrstedt

, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27: v119–v133.

10.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis, version 3.2018.

11.

Yahata

Kobayashi

Sonoda

, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 2016; 21: 491–497.

12.

Hesketh

Schnadig

Schwartzberg

, et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 2016; 122: 2418–2425.

13.

Tanioka

Kitao

Matsumoto

, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013; 109: 859–865.

14.

Hesketh

Rossi

Rizzi

, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25: 1340–1346.

15.

Aapro

Rugo

Rossi

, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328–1333.

16.

Gralla

Bosnjak

Hontsa

, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25: 1333–1339.

17.

Jordan

Gralla

Rizzi

, et al. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 2016; 24: 4617–4625.

18.

Bošnjak

Stamatovic

Borroni

, et al. Efficacy and safety of oral NEPA (netupitant/palonosetron), the first fixed-combination antiemetic, in patients with gynecological cancers receiving platinum-based chemotherapy. Int J Gynecol Cancer 2018; 28: 1153–1161.

19.

Jordan

Sippel

Schmoll

Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.

Oncologist 2007; 12: 1143–1150.

20.

Gralla

Lichinitser

Van Der Vegt

, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570–1577.

21.

Jordan

Blättermann

Hinke

, et al. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? – A systematic review and meta-analysis. Support Care Cancer 2018; 26: 21–32.